Determination of CYP3A activity in patients using plasma amlodipine exposure and metabolism

Determination of CYP3A activity in patients using plasma amlodipine exposure and metabolism - Determination of CYP3A activity using plasma amlodipine exposure and metabolism

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033745

Enrollment

200

Registered

2018-08-14

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with AML besylate tablets

Exclusion criteria

Exclusion criteria: Patients from whom written informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
Assessment of CYP3A activity by determining amlodipine and its two metabolites (dehydroamlodipine and O-des[2-aminoethyl]-O-carboxymethyl dehydroamlodipine) in Human Plasma	—

Secondary

Measure	Time frame
Assessment of CYP3A activity by determining plasma 4beta-hydroxycholesterol as an endogenous CYP3A metric	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital Pharmacy

naitou@hama-med.ac.jp053-435-2623

Outcome results